Latest news with #ACLF
Yahoo
14 hours ago
- Business
- Yahoo
Shift Toward Targeted Drug Delivery Systems and Non-invasive Treatment Options is Poised to Transform the Landscape
The global acute on chronic liver failure (ACLF) market is witnessing a transformation with a focus on innovative solutions like gene therapies and regenerative medicine. These advancements offer new ways to tackle the condition's root causes, while targeted drug delivery systems and non-invasive treatments promise more effective, patient-friendly options. However, the lack of FDA-approved therapies limits market growth. North America is expected to lead due to its robust healthcare infrastructure. Key market drivers include rising investments in R&D and the increasing prevalence of liver diseases. Companies like Grifols Therapeutics, GENFIT, and Martin Pharmaceuticals are pioneering progress in this burgeoning field. Dublin, June 24, 2025 (GLOBE NEWSWIRE) -- The "Acute On Chronic Liver Failure Market - A Global and Regional Analysis: Focus on Country and Regional Analysis - Analysis and Forecast, 2025-2035" report has been added to growing focus on innovative solutions like gene therapies and regenerative medicine technologies offers significant potential for the global acute on chronic liver failure market, introducing new ways to address the root causes of the condition. Additionally, the shift toward targeted drug delivery systems and non-invasive treatment options is poised to transform the treatment landscape, providing more effective and patient-friendly alternatives that could further propel market the lack of FDA-approved therapies for acute on chronic liver failure remains a key challenge, limiting the availability of effective treatment options and hindering market expansion. On a positive note, the continuous improvement of healthcare infrastructure in emerging economies presents a considerable opportunity for market growth, as increased access to treatments becomes more America is expected to dominate the global acute on chronic liver failure market due to established healthcare systems, high treatment adoption rates, and significant investments in healthcare infrastructure. Key Market Players and Competition SynopsisThe companies profiled in this report are based on extensive research and insights from primary experts, evaluating company coverage, product portfolios, and market penetration. The leading players in the global acute on chronic liver failure market include pharmaceutical companies making significant advancements in therapies for liver failure. These companies play a crucial role in improving patient outcomes and addressing the growing demand for effective treatments for liver diseases. How Can This Report Add Value to an Organization?Product/Innovation Strategy: This report provides comprehensive insights into the current treatments and market trends for acute on chronic liver failure, helping organizations identify opportunities for new product development. By focusing on unmet needs, particularly in the areas of antiviral therapies, liver support agents, and organ transplantation, companies can innovate to meet the growing demand for effective ACLF Strategy: To maintain a competitive edge in the acute on chronic liver failure market, companies should focus on improving the safety and efficacy of existing treatments, advancing liver transplantation technologies, and exploring strategic partnerships with research institutions and healthcare providers. Expanding market access in emerging markets and investing in public awareness campaigns will also be critical to gaining market - Drivers and Limitations The demand drivers for the global acute on chronic liver failure market are: Ongoing investment in research and development of new drug classes, including antivirals and immunosuppressants for acute on chronic liver failure, is propelling market growth The rising prevalence of chronic liver diseases, especially cirrhosis and chronic hepatitis, is contributing to a higher occurrence of acute on chronic liver failure, thereby fuelling the demand for effective treatments Limitations: The lack of FDA-approved therapies for acute on chronic liver failure restricts access to effective treatments, impeding market growth Some of the prominent pharmaceutical companies established in the global acute on chronic liver failure market include: Grifols Therapeutics LLC GENFIT Corp Martin Pharmaceuticals Key Topics Covered: 1. Global Acute On Chronic Liver Failure Market: Industry Outlook1.1 Market Overview and Ecosystem1.2 Epidemiological Analysis of Acute On Chronic Liver Failure1.2.1 By Region1.3 Market Trends1.4 Clinical Trial Analysis1.4.1 By Phase1.5 Regulatory Landscape Analysis1.5.1 Legal Requirement and Framework in U.S.1.5.2 Legal Requirement and Framework in E.U.1.5.3 Legal Requirement and Framework in Asia-Pacific1.6 Market Dynamics1.6.1 Impact Analysis1.6.2 Market Drivers1.6.3 Market Restraints1.6.4 Market Opportunities2. Global Acute On Chronic Liver Failure Market, by Region, $Million, 2023-20352.1 North America2.1.1 Key Findings2.1.2 Market Dynamics2.1.3 Market Sizing and Forecast2.1.3.1 North America Acute On Chronic Liver Failure Market (by Country)2.1.3.1.1 U.S.2.2 Europe2.2.1 Key Findings2.2.2 Market Dynamics2.2.3 Market Sizing and Forecast2.2.3.1 Europe Acute On Chronic Liver Failure Market (by Country)2.2.3.1.1 Germany2.2.3.1.2 France2.2.3.1.3 Italy2.2.3.1.4 U.K.2.3 Asia-Pacific2.3.1 Key Findings2.3.2 Market Dynamics2.3.3 Market Sizing and Forecast2.3.3.1 Asia-Pacific Acute On Chronic Liver Failure Market (by Country)2.3.3.1.1 Japan2.4 Rest-of-the-World2.4.1 Key Findings2.4.2 Market Dynamics2.4.3 Market Sizing and Forecast3. Global Acute On Chronic Liver Failure Market: Competitive Benchmarking and Company Profiles3.1 Competitive Landscape3.1.1 Key Strategies and Developments by Company3.1.1.1 Funding Activities3.1.1.2 Mergers and Acquisitions3.1.1.3 Regulatory Approvals3.1.1.4 Partnerships, Collaborations and Business Expansions3.1.2 Key Developments Analysis3.2 Company Profiles3.2.1 Grifols Therapeutics LLC3.2.1.1 Company Overview3.2.1.2 Product Portfolio3.2.1.3 Target Customers/End Users3.2.1.4 Key Personnels3.2.1.5 Analyst View3.2.2 GENFIT Corp3.2.2.1 Company Overview3.2.2.2 Product Portfolio3.2.2.3 Target Customers / End Users3.2.2.4 Key Personnels3.2.2.5 Analyst View3.2.3 Martin Pharmaceuticals3.2.3.1 Company Overview3.2.3.2 Product Portfolio3.2.3.3 Target Customers / End Users3.2.3.4 Key Personnels3.2.3.5 Analyst View4. Research Methodology For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Yahoo
17-06-2025
- Business
- Yahoo
GENFIT: June 17, 2025 Combined Shareholders Meeting Results
All resolutions recommended by the Board of Directors approved (quorum: 27.21%). Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), June 17, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the results of the Combined Shareholders Meeting which took place on June 17, 2025. The quorum on first convening amounted to 27.21% and shareholders approved all of the resolutions, with the exception of resolution n°28 which was rejected in accordance with the recommendations of the Board of Directors. The voting results, resolution by resolution, are available in the Investors & Media section of the Company's website (Shareholders Meeting | GENFIT). ABOUT GENFIT GENFIT is a biopharmaceutical company committed to improving the lives of patients with rare, life-threatening liver diseases whose medical needs remain largely unmet. GENFIT is a pioneer in liver disease research and development with a rich history and a solid scientific heritage spanning more than two decades. Today, GENFIT has built up a diversified and rapidly expanding R&D portfolio of programs at various stages of development. The Company focuses on Acute-on-Chronic Liver Failure (ACLF). Its ACLF franchise includes five assets under development: VS-01, G1090N, SRT-015, CLM-022 and VS-02-HE, based on complementary mechanisms of action using different routes of administration. Other assets target other serious diseases, such as cholangiocarcinoma (CCA), urea cycle disorder (UCD) and organic acidemia (OA). GENFIT's expertise in the development of high-potential molecules from early to advanced stages, and in pre-commercialization, was demonstrated in the accelerated approval of Iqirvo® (elafibranor1) by the U.S. Food and Drug Administration, the European Medicines Agency and the Medicines and Healthcare Regulatory Agency in the UK for Primary Biliary Cholangitis (PBC). Beyond therapies, GENFIT also has a diagnostic franchise including NIS2+® in Metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH for non-alcoholic steatohepatitis) and TS-01 focusing on blood ammonia levels. GENFIT is headquartered in Lille, France and has offices in Paris (France), Zurich (Switzerland) and Cambridge, MA (USA). The Company is listed on the Nasdaq Global Select Market and on the Euronext regulated market in Paris, Compartment B (Nasdaq and Euronext: GNFT). In 2021, Ipsen became one of GENFIT's largest shareholders, acquiring an 8% stake in the Company's capital. FORWARD LOOKING STATEMENTS This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, such as "believe", "potential", "expect", 'target', 'may', 'will', "should", "could", "if" and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on the current expectations and reasonable assumptions of the Company's management, these forward-looking statements are subject to numerous known and unknown risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include, among others, the uncertainties inherent in research and development, including in relation to safety of drug candidates, cost of, progression of, and results from, our ongoing and planned clinical trials, patient recruitment, review and approvals by regulatory authorities in the United States, Europe and worldwide, of our drug and diagnostic candidates, pricing, approval and commercial success of elafibranor in the relevant jurisdictions, exchange rate fluctuations, and our continued ability to raise capital to fund our development, as well as those risks and uncertainties discussed or identified in the Company's public filings with the AMF, including those listed in Chapter 2 "Risk Factors and Internal Control" of the Company's 2024 Universal Registration Document filed on April 29, 2025 (no. 25-0331) with the Autorité des marchés financiers ("AMF"), which is available on GENFIT's website ( and the AMF's website ( and those discussed in the public documents and reports filed with the U.S. Securities and Exchange Commission ("SEC"), including the Company's 2024 Annual Report on Form 20-F filed with the SEC on April 29, 2025 and subsequent filings and reports filed with the AMF or SEC or otherwise made public, by the Company. In addition, even if the results, performance, financial position and liquidity of the Company and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. These forward-looking statements speak only as of the date of publication of this press release. Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements, whether as a result of new information, future events or otherwise. CONTACT GENFIT | InvestorsTel: +33 3 2016 4000 | investors@ PRESS RELATIONS | MediaStephanie Boyer – Press relations | Tel: +333 2016 4000 | GENFIT | 885 Avenue Eugène Avinée, 59120 Loos - FRANCE | +333 2016 4000 | 1 Elafibranor is marketed and commercialized in the U.S by Ipsen under the trademark Iqirvo®. Attachment GENFIT June 17, 2025 Combined Shareholders Meeting ResultsError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16-04-2025
- Business
- Yahoo
FDA clears eGenesis' genetically engineered porcine liver for Phase I trial
eGenesis has gained US Food and Drug Administration (FDA) clearance on an investigational new drug (IND) application for a genetically engineered porcine (pig) liver. The organ is designed for use with OrganOx's extracorporeal liver cross-circulation (ELC) system for patients with acute-on-chronic liver failure (ACLF). The biotech and medtech companies entered an exclusive clinical co-development agreement last year to advance their respective technologies in combination. Research indicates that around 35,000 patients in the US are hospitalised for ACLF each year. Meanwhile, most individuals wait between three and five years for a kidney, as per the American Kidney Fund. eGenesis' pig liver is intended to draw down on the mortality rates in patients awaiting a transplant. The Phase I trial plans to enrol 20 patients with ACLF (Grade 2 to Grade 3) and hepatic encephalopathy (≤ Grade 3), who are ineligible for transplant, across multiple US centres. eGenesis' EGEN-5784 pig liver in combination with OrganOx's ELC is intended to support the function of patients' decompensated liver, potentially allowing for the recovery of a patient's native liver or providing sufficient time to receive a liver transplant. eGenesis CEO Michael Curtis commented: 'The FDA's clearance of EGEN-5784 in combination with the OrganOx ELC system represents a significant advance towards fulfilling our mission to develop safe and effective human-compatible organs that have the potential to transform the treatment of organ failure and extend patients' lives. Last year, OrganOx and eGenesis completed their first extracorporeal perfusion of a research donor using their combined offerings. The process involved circulating a recently deceased donor's blood through the genetically engineered EGEN-5784 pig liver outside of their body, with the donor being the first to be enrolled in the companies' ongoing PERFUSE-2 study. In the first procedure, stable blood flow, pressure, and pH were maintained throughout the procedure, with no evidence of rejection observed, with the perfusion electively stopped, per-protocol, at 72 hours, with the liver appearing healthy. Last year, eGenesis became the first company to successfully implant a pig kidney into a living patient at Massachusetts General Hospital (MGH) under the FDA's expanded access programme and concluded a $191m Series D financing round to continue the development of EGEN-5784. While Rick Slayman, the end-stage kidney disease patient who received the implant, died two months later, MGH stated there was no indication that the death was a result of the transplant. "FDA clears eGenesis' genetically engineered porcine liver for Phase I trial" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
